Tyrosine Kinases / Adaptors
VEGF-B Antibody
|
イイネ！(0)
| 
|
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報 カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #2463S | 100 μL | 46,000 | |
|
2463 の推奨プロトコール
最適な結果を得るために：Cell Signaling Technology (CST) 社は、各製品の推奨プロトコールを使用することを強くお薦めいたします。
推奨プロトコールはCST社内試験の徹底的なバリデーションに基づいて作成されておりますので、正確かつ再現性の高い結果が得られます。
注：各製品に最適化されたプロトコールをリンクしています。
| | |
-
2463:
-
Western Blotting
| 用途（希釈倍率） | |
| ウエスタンブロッティング(1:1,000) |
| 特異性・感度 | |
| 様々な濃度の組換えヒトVEGF-Bタンパク質を検出します。他のVEGFファミリータンパク質とは交差しません。 |
| 使用抗原 | |
| マウスVEGF-B タンパク質のGly155周辺領域（合成ペプチド） |
Western Blotting
Western blot analysis of recombinant human VEGF-B proteins at various concentrations, using VEGF-B Antibody.
Vascular endothelial growth factor (VEGF) is a highly specific mitogen for vascular endothelial cells. VEGF and its close relatives VEGF-B, -C and -D form a subfamily within PDGF family of growth factors, which belongs to the cysteine knot class of cytokines. Five VEGF isoforms of 121, 145, 165, 189 and 206 amino acids (VEGF121–206) are generated as a result of alternative splicing from a single VEGF gene (1).The various VEGF forms bind to three tyrosine-kinase receptors, VEGFR-1, VEGFR-2 and VEGFR-3 which are expressed almost exclusively in endothelial cells. VEGFR-2 is the main angiogenic signal transducer for VEGF, while VEGFR-3 is specific for VEGF-C and -D and is necessary and sufficient for lymphangiogenic signaling. However, upon proteolytic processing VEGF-C and -D gain the ability to also bind and activate VEGFR-2 (2). Guided by the binding properties of the ligands, the VEGFRs are able to form both homodimers and heterodimers. Receptor dimerization is accompanied by activation of receptor kinase activity leading to receptor autophosphorylation. Phosphorylated receptors recruit interacting proteins and induce downstream signaling (3). Recently, tumor therapies based on neutralizing anti-VEGF antibodies and small molecule tyrosine kinase inhibitors targeting VEGFRs have been developed. These new strategies for tumor treatment show the clinical relevance of inhibiting VEGF signal transduction pathways that are exaggerated in pathological angiogenesis (4).
-
Olsson, A.K. et al. (2006) Nat. Rev. Mol. Cell Biol. 7, 359-371.
-
Gluzman-Poltorak, Z. et al. (2001) J. Biol. Chem. 276, 18688-18694.
-
Matsumoto, T. and Mugishima, H. (2006) J. Atheroscler. Thromb. 13, 130-135.
-
Gatto, B. and Cavalli, M. (2006) Anticancer Agents Med. Chem. 6, 287-301.
PhosphoSitePlus®：
VEGFB